Full text is available at the source.
Design, Synthesis, and Biological Evaluation of Thiazolidine‐2,4‐dione Conjugates as PPAR‐γ Agonists
Design, Creation, and Testing of Compounds that Activate PPAR-γ Receptors
AI simplified
Abstract
Compounds 5l and 5m demonstrated 54.21% and 55.41% PPAR-γ transactivation, respectively, comparable to standard drugs.
- Both compounds significantly lowered blood glucose levels in STZ-induced diabetic rats.
- Compounds 5l and 5m showed greater reductions in liver enzymes AST, ALT, and ALP than the standard drug pioglitazone.
- Compound 5m led to a significant increase in PPAR-γ gene expression by 2.00-fold, higher than pioglitazone and rosiglitazone.
- No liver damage was observed with compounds 5l and 5m, suggesting potential safety for antidiabetic applications.
AI simplified